09-08-2025
Veracyte price target lowered to $28 from $29 at Morgan Stanley
Morgan Stanley analyst Tejas Savant lowered the firm's price target on Veracyte (VCYT) to $28 from $29 and keeps an Underweight rating on the shares. The company reported a solid Q2 beat on continued Decipher/Afirma momentum leading to a 2025 guidance raise, the analyst tells investors in a research note. The firm added that Veracyte's pipeline is promising an represents substantial opportunity, though meaningful upside remains a 2027+ dynamic.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
